Abstract: FR-PO755
Effects of Medium Cut-Off (Theranova) Dialyzer on Hemodialysis Patients: A Prospective, Cross-Over Study
Session Information
- Dialysis: Inflammation and Infection
October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Author
- Cozzolino, Mario, Department of Health Sciences, University of Milan, Milan, Italy
Background
Recent data suggest that expanded hemodialysis (HDx) enabled by middle cut-off membrane promotes greater clearance for large middle molecules implicated in inflammation and immune function modulation.
Methods
In prospective, open-label, controlled, crossover pilot study, 20 prevalent hemodialysis (HD) patients were studied for 6 months in two dialysis treatments as follows: one MCO (Theranova) dialyzer and one high-flux dialyzer.
Results
In table 1, we present the baseline characteristics of HD patients. Hemoglobin, ferritin, transferrin, calcium, phosphate, parathyroid hormone and 25(OH) vitamin D levels were similar with MCO and high-flux HD. In addition, we did not find any albumin loss in the two treatment groups. Also, dialysis adequacy was similar in MCO and high-flux HD treated patients. Interestingly, the cumulative number of episodes of infection, confirmed clinically and treated with antibiotics) was significantly lower in HDx (# 6), compared with high-flux HD patients (# 20) (Figure 1), while number of hospitalizations did not change.
Conclusion
In conclusion, our pilot study demonstrates that Theranova dialyzer has a good tolerance profile and, intriguingly, reduces the cumulative number of infections in HD patients.
Funding
- Commercial Support –